Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 225,103 Incyte Co. (NASDAQ:INCY)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Incyte Co. (NASDAQ:INCY - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 225,103 shares of the biopharmaceutical company's stock, valued at approximately $15,548,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.12% of Incyte as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in INCY. Retirement Systems of Alabama lifted its position in Incyte by 0.4% during the fourth quarter. Retirement Systems of Alabama now owns 34,620 shares of the biopharmaceutical company's stock valued at $2,391,000 after buying an additional 139 shares during the period. Nissay Asset Management Corp Japan ADV lifted its position in Incyte by 0.7% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 20,371 shares of the biopharmaceutical company's stock valued at $1,410,000 after buying an additional 150 shares during the period. Trust Point Inc. lifted its position in Incyte by 5.0% during the fourth quarter. Trust Point Inc. now owns 3,282 shares of the biopharmaceutical company's stock valued at $227,000 after buying an additional 156 shares during the period. Bank of Nova Scotia lifted its position in Incyte by 0.8% during the fourth quarter. Bank of Nova Scotia now owns 21,694 shares of the biopharmaceutical company's stock valued at $1,498,000 after buying an additional 171 shares during the period. Finally, Mather Group LLC. lifted its position in Incyte by 26.4% during the fourth quarter. Mather Group LLC. now owns 828 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 173 shares during the period. Institutional investors own 96.97% of the company's stock.

Insiders Place Their Bets

In other Incyte news, EVP Sheila A. Denton sold 599 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $69.99, for a total value of $41,924.01. Following the completion of the transaction, the executive vice president now directly owns 25,848 shares in the company, valued at $1,809,101.52. This represents a 2.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Barry P. Flannelly sold 19,807 shares of the company's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $67.69, for a total value of $1,340,735.83. Following the completion of the transaction, the executive vice president now owns 33,567 shares of the company's stock, valued at $2,272,150.23. The trade was a 37.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.80% of the stock is owned by company insiders.

Incyte Stock Performance

Shares of NASDAQ:INCY traded down $0.79 during midday trading on Friday, hitting $65.25. The company had a trading volume of 3,737,618 shares, compared to its average volume of 2,289,471. The company has a market cap of $12.63 billion, a price-to-earnings ratio of 241.68, a PEG ratio of 0.41 and a beta of 0.68. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.97 and a quick ratio of 1.94. The company has a fifty day moving average of $60.80 and a two-hundred day moving average of $67.52. Incyte Co. has a 12-month low of $53.56 and a 12-month high of $83.95.

Incyte (NASDAQ:INCY - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $1.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.15. Incyte had a net margin of 0.77% and a return on equity of 0.05%. The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $996.17 million. During the same period in the prior year, the firm posted $0.64 EPS. The firm's quarterly revenue was up 19.5% compared to the same quarter last year. On average, equities research analysts expect that Incyte Co. will post 4.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. William Blair lowered Incyte from an "outperform" rating to a "market perform" rating in a research report on Tuesday, March 18th. Citigroup lowered their price target on Incyte from $97.00 to $88.00 and set a "buy" rating for the company in a research report on Tuesday, February 11th. Truist Financial lifted their price target on Incyte from $72.00 to $73.00 and gave the stock a "hold" rating in a research report on Tuesday. Royal Bank of Canada lifted their price target on Incyte from $64.00 to $67.00 and gave the stock a "sector perform" rating in a research report on Wednesday, April 30th. Finally, Morgan Stanley lowered their price target on Incyte from $69.00 to $65.00 and set an "equal weight" rating for the company in a research report on Monday, March 24th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Incyte presently has a consensus rating of "Hold" and an average target price of $73.60.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.